A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T, Tome Y, Murakami T, Miyake K, Igarashi K, Kawaguchi K, Oshiro H, Higuchi T, Miyake M, Sugisawa N, Zhang Z, Razmjooei S, Wangsiricharoen S, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Eckardt MA, Singh AS, Chawla S, Kanaya F, Eilber FC, Singh SR, Zhao M, Hoffman RM.
Kiyuna T, et al. Among authors: miyake k, miyake m.
Biochem Biophys Res Commun. 2018 Nov 2;505(3):733-739. doi: 10.1016/j.bbrc.2018.09.106. Epub 2018 Oct 3.
Biochem Biophys Res Commun. 2018.
PMID: 30292411